Vidaza® (Azacitidine) CML Chronic Myeloid Leukemia
CLINICAL TRIALS
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)
Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia
Azacitidine Maintenance Therapy After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia (CML)
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute
Myeloid Leukemia (AML)
A Study of 5-Azacitidine (Vidaza®)in Patients With Chronic Myelomonocytic Leukemia
Study of Vidaza® (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia (ABRAZA)
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)
Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia
Azacitidine Maintenance Therapy After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia (CML)
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute
Myeloid Leukemia (AML)
A Study of 5-Azacitidine (Vidaza®)in Patients With Chronic Myelomonocytic Leukemia
Study of Vidaza® (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia (ABRAZA)
